Clinical Trial Update: Safety and Effectiveness of Visipaque 320mg-I/ml for Use in Contrast-Enhanced CT Angiography of Arteries of the Heart [Phase 3]

View source ↗

Summary

Phase 3 trial update on safety and effectiveness of Visipaque 320 mg-I/mL for contrast-enhanced CT angiography of coronary arteries, terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• VISIPAQUE (IODIXANOL)

Snippet

Sponsor: GE Healthcare | Conditions: Coronary Artery Disease | Phase 3 | Status: TERMINATED